To achieve
this, an acute study (single dose ingestion with 4 h follow up) was
conducted to establish the feasibility of the use of a low intake of LC n
−3 PUFA, delivered as MTO-enriched bread. This was followed by a
3 week chronic study using commercial MTO bread as the LC n−3
PUFA source. They found that low dose MTO-enriched bread did
improve plasma LC n−3 PUFA status in both the acute and the chronic
study. In other words, the LC n−3 PUFA in the MTO-enriched bread
was bio-available